Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.

Disclosure: The author does not hold a position in NTLA.

← Back to Free Index

NTLA

Analysis as of: 2026-08-07

Intellia Therapeutics, Inc.

Intellia develops CRISPR-based gene editing therapies, led by lonvo-z for hereditary angioedema and nex-z for transthyretin amyloidosis.

biotech healthcare

On Yahoo Finance ...

Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Clinical proof nears commercial proof

A first approved in vivo gene-editing therapy could turn a high-burn platform into a focused rare-disease franchise. The upside is real, but it is still gated by filing, reimbursement and physician comfort with irreversible treatment.

Analysis

Thesis

If lonvo-z clears filing, approval and launch, Intellia can convert from a collaboration-funded CRISPR platform into a focused rare-disease franchise; first commercial validation matters more than near-term revenue because it can de-risk the broader in vivo editing stack, though upside is capped if payer adoption and nex-z breadth lag.

Last Economy Alignment

Positive but not elite: AI should lower discovery and execution cost, while Intellia still owns the scarce trust layer in gene editing through IP, CMC execution, regulator-facing evidence and treatment workflow.

Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple

4.1x (from 5 most recent analyses)

Reasoning

This is a conversion story, not a pure discovery story. A successful lonvo-z launch would move Intellia from low-quality collaboration revenue toward a real rare-disease franchise, while proving its in vivo editing stack can survive the hardest gate: regulators and payers. That should earn a meaningful rerating, but concentration in one lead asset and unfinished ATTR validation keep the upside below the most aggressive platform narratives.

Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary

The key risk is not science alone; it is whether Intellia converts positive lonvo-z data into a completed filing, FDA acceptance, a usable label, payer access and physician willingness to use an irreversible therapy. If nex-z fails to restore second-asset credibility, NTLA could remain a concentrated one-product biotech with ongoing burn and a limited rerating.

Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Trends

Key Changes

July 30, 2026: management scheduled the August 6 second-quarter update, concentrating attention on cash use and whether lonvo-z BLA completion still tracks for 2H26.
No accessible primary-source disclosure in the last 7-10 days changed the core setup: lonvo-z BLA completion and MAGNITUDE-2 enrollment remain the near-term repricing gates.
The setup is now less about whether HAELO worked and more about whether Intellia can execute the regulatory handoff without slippage.

Forecast update

Clinical confidence improved, but extra shares outstanding and the still-unfinished regulatory handoff temper upside capture per share.

Upgrade to Builder to also access: Future Considerations

Last Economy Structure

AI Industrial Score

0.35

They do not win because AI thinks for them; they win if they own the hard part: trusted gene-editing know-how, manufacturing and regulator-ready data. AI can speed discovery, but approval, safety and payer trust are the real gates, so the score is positive rather than exceptional.

Upgrade to Reader to also access: Score Decomposition, Confidence Level

Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility

Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target

$20.85

Upgrade to Reader to also access: Bull Case, Base Case, Bear Case

Next Arc Research